Neoplasms

Blood and Lymph Conditions

All Conditions

Hematologic Neoplasms

Hematologic Diseases

Biomarker-enriched advanced hematological neoplasms

Other selected advanced hematological neoplasms

Weekly infusion of BAY1251152 in 21-day cycles.

BAY1251152

Bayer Study Director

The purpose of this study is to identify the most appropriate dose that can be safely administered and that can have an effect on blood cancer cells. Once that safe dose is identified, additional patients will be asked to join the study to further evaluate the safety and effectiveness of the study drug. The study will also investigate the pharmacokinetics (study of what the body does to the drug), as well as pharmacodynamics (study of what the drug does to the body), which may provide information about the effects of BAY 1251152. The study will also measure some biological markers (markers of biological activity in your body) that can be used to predict the response and safety of the proposed treatment.

Phase I Trial of BAY1251152 for Advanced Blood Cancers

An Open-label, Multicenter Phase I Study to Characterize the Safety, Tolerability, Preliminary Anti-tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of BAY1251152 in Patients With Advanced Hematological Malignancies

To determine the MTD of BAY1251152 in subjects with advanced hematological neoplasms

To determine the RP2D of BAY1251152 based on safety, tolerability, pharmacokinetic, and pharmacodynamic data in subjects with advanced hematological neoplasms

For assessment of the safety (ECG, vital signs, clinical significant abnormal laboratory results... etc.)and tolerability of BAY 1251152 in subjects with advanced hematological neoplasms

To assess the clinical efficacy of BAY 1251152 in subjects with advanced hematological neoplasms

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Phase I Trial of BAY1251152 for Advanced Blood Cancers	NCT02745743	Hematologic Neo...	BAY1251152	18 Years -	Bayer
Phase I Trial of BAY1251152 for Advanced Blood Cancers	NCT02745743	Hematologic Neo...	BAY1251152	18 Years -	Bayer

Spots Global Cancer Trial Database for bay1251152

Every month we try and update this database with for bay1251152 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for bay1251152

Every month we try and update this database with for bay1251152 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for bay1251152 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.